Absci Initiates First-in-Human Trial of AI-Designed Antibody ABS-201 for Hair Loss Treatment
核心洞察
Absci Corporation (搜索) has dosed the first participants in its Phase 1/2a HEADLINE trial evaluating ABS-201, an AI-designed anti-prolactin receptor (搜索) antibody for androgenetic alopecia (搜索) treatment.
The novel therapeutic targets prolactin receptors to stimulate hair follicle regeneration, representing a scientifically distinct approach that works upstream of testosterone and DHT pathways.
ABS-201 demonstrated statistically significant superior hair regrowth compared to minoxidil in preclinical mouse models, with interim clinical data expected in the second half of 2026.
Absci Corporation (搜索) has achieved a significant milestone in regenerative medicine by dosing the first healthy volunteers in its Phase 1/2a HEADLINE study of ABS-201, an investigational anti-prolactin receptor (搜索) (PRLR (搜索)) antibody engineered using the company's generative AI platform. The randomized, double-blind, placebo-controlled first-in-human study will enroll up to 227 healthy volunteers with or without androgenetic alopecia (搜索) (AGA) to evaluate safety, tolerability, and efficacy of this novel therapeutic approach.
Novel Mechanism Targets Hair Growth Regulation
ABS-201 represents a fundamentally different approach to treating androgenetic alopecia (搜索), which affects approximately 80 million Americans. Unlike current FDA-approved treatments minoxidil and finasteride, which show limited efficacy and notable side effects, ABS-201 directly targets the prolactin receptor (搜索), a known driver of catagen, the regression phase of the hair cycle.
"The scientific premise behind ABS-201 is compelling. It directly targets the prolactin receptor (搜索), a known driver of catagen, the regression phase of the hair cycle," said Rodney Sinclair, MD, Professor of Dermatology at the University of Melbourne and principal investigator. "Blocking prolactin signaling effectively removes the 'hand-brake' on hair growth. This approach works upstream of testosterone and DHT. It acts earlier in the balding process and before miniaturization."
In preclinical studies, the antibody demonstrated statistically significant superior hair regrowth compared to minoxidil in a preclinical mouse model, providing strong evidence for its therapeutic potential.
Comprehensive Trial Design and Timeline
The Phase 1/2a HEADLINE trial follows a structured approach with primary endpoints focused on safety and tolerability. Secondary endpoints include pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and efficacy readouts measuring target area hair count (TAHC), target area hair width (TAHW), target area darkening/pigmentation (TAHD), and patient/investigator reported outcome measures.
The study begins with a single ascending dose (SAD) portion testing approximately 4-6 IV dose groups for safety, tolerability, PK and PD. Following the SAD portion, a multiple ascending dose (MAD) portion will test approximately 3-4 subcutaneous dose groups in healthy volunteers with androgenetic alopecia (搜索).
The MAD portion is specifically powered to demonstrate human proof-of-concept for ABS-201's ability to treat androgenetic alopecia (搜索) by stimulating significant hair regrowth. Absci believes successful results from this trial will position the program for accelerated registrational trials, with interim efficacy data anticipated in the second half of 2026.
Dual Indication Strategy
Beyond hair loss treatment, Absci announced in November 2025 that it will pursue endometriosis (搜索) as an additional indication for ABS-201. Endometriosis affects an estimated 5-10% of women of reproductive age worldwide, including approximately 9 million women in the US. The inflammatory disease, defined by endometrial-like lesions found outside the uterine lining, causes pelvic pain, heavy bleeding, infertility, and ovarian cysts, with no current medical or surgical cure.
The company plans to leverage safety, tolerability, and PK data from the AGA trial to enable Phase 2 clinical development in endometriosis (搜索). Absci expects to initiate Phase 2 clinical development of ABS-201 in endometriosis in the fourth quarter of 2026, with an interim readout anticipated in the second half of 2027.
AI-Driven Drug Discovery Platform
ABS-201 exemplifies Absci's Integrated Drug Creation platform, which combines cutting-edge AI models with a synthetic biology data engine. The approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation, with each cycle refining data and strengthening models to facilitate rapid innovation and enhance therapeutic design precision.
"This milestone represents a truly exciting and transformative leap forward for regenerative biology," said Sean McClain, Founder & CEO. "We believe this program highlights the massive leverage in our business model: using our AI engine to unlock high-value biological targets like PRLR (搜索), and then efficiently navigating clinical development to address significant unmet needs in both dermatology and women's health."
The company characterizes ABS-201 as well-positioned to be best-in-class with respect to the anti-prolactin receptor (搜索) mechanism based on its affinity, superior half-life and bioavailability in non-human primates, and high concentration formulation.
Market Opportunity and Clinical Development Path
Absci will host a virtual key opinion leader seminar on December 11 to discuss the anticipated clinical development path, market opportunity, and differentiated profile of the ABS-201 program. The company will also disclose additional human ex vivo data that further supports the PRLR (搜索) mechanism of action underlying this program.
"Current treatments for androgenetic alopecia (搜索) and endometriosis (搜索) are often characterized by limited efficacy and significant side effects," said Andreas Busch, PhD, Chief Innovation Officer at Absci. "As prolactin has been demonstrated to be a key driver for both hair loss and endometriosis, this offers us a novel pathway for treatment for these patients."